Une étude pour évaluer l'efficacité, l'innocuité et la pharmacocinétique de l'EYU688 chez les patients atteints de dengue
Une étude en groupe parallèle, randomisée, à l'aveugle des participants et des enquêteurs, contrôlée par placebo, pour évaluer l'efficacité, l'innocuité et la pharmacocinétique de l'EYU688 chez les patients atteints de dengue
The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
This is a randomized, participant- and investigator- blinded, placebo-controlled study to investigate the efficacy and safety of EYU688 administered orally in patients with dengue fever.
Due to the different PK sampling schedules applied, the study consists of two cohorts run in parallel (intensive PK [cohort 1] and sparse PK sampling [cohort 2]).
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- Phase 2
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Novartis Pharmaceuticals
- Numéro de téléphone: +41613241111
- E-mail: novartis.email@novartis.com
Sauvegarde des contacts de l'étude
- Nom: Novartis Pharmaceuticals
Lieux d'étude
-
-
Amazonas
-
Manaus, Amazonas, Brésil, 69040-000
- Recrutement
- Novartis Investigative Site
-
-
Federal District
-
Brasília, Federal District, Brésil, 71635-580
- Recrutement
- Novartis Investigative Site
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brésil, 90560-032
- Recrutement
- Novartis Investigative Site
-
-
Rio de Janeiro
-
Rio de Janeiro, Rio de Janeiro, Brésil, 21040-360
- Recrutement
- Novartis Investigative Site
-
-
São Paulo
-
Sorocaba, São Paulo, Brésil, 18040-425
- Recrutement
- Novartis Investigative Site
-
São Caetano do Sul, São Paulo, Brésil, 09521-160
- Recrutement
- Novartis Investigative Site
-
São José do Rio Preto, São Paulo, Brésil, 15090 000
- Recrutement
- Novartis Investigative Site
-
-
-
-
Atlántico
-
Barranquilla, Atlántico, Colombie, 080012
- Recrutement
- Novartis Investigative Site
-
-
Santander Department
-
Bucaramanga, Santander Department, Colombie, 681017
- Recrutement
- Novartis Investigative Site
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombie, 760032
- Recrutement
- Novartis Investigative Site
-
-
-
-
Karnataka
-
Belagavi, Karnataka, Inde, 590010
- Recrutement
- Novartis Investigative Site
-
-
Maharashtra
-
Mumbai, Maharashtra, Inde, 400008
- Retiré
- Novartis Investigative Site
-
Pune, Maharashtra, Inde, 411013
- Recrutement
- Novartis Investigative Site
-
-
Rajasthan
-
Jaipur, Rajasthan, Inde, 302017
- Recrutement
- Novartis Investigative Site
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, Inde, 600113
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Kuala Selangor, Malaisie, 68000
- Recrutement
- Novartis Investigative Site
-
-
Pahang
-
Kuantan, Pahang, Malaisie, 25200
- Recrutement
- Novartis Investigative Site
-
-
Perak
-
Ipoh, Perak, Malaisie, 30450
- Recrutement
- Novartis Investigative Site
-
-
Pulau Pinang
-
Seberang Jaya, Pulau Pinang, Malaisie, 13700
- Recrutement
- Novartis Investigative Site
-
-
Sarawak
-
Miri, Sarawak, Malaisie, 98000
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Oaxaca City, Mexique, 68020
- Recrutement
- Novartis Investigative Site
-
Veracruz, Mexique, 91855
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Singapore, Singapour, 169608
- Recrutement
- Novartis Investigative Site
-
-
Singapore
-
Singapore, Singapore, Singapour, 308433
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Haiphong, Viêt Nam, 180000
- Recrutement
- Novartis Investigative Site
-
Hanoi, Viêt Nam, 100000
- Recrutement
- Novartis Investigative Site
-
Ho Chi Minh City, Viêt Nam, 700000
- Recrutement
- Novartis Investigative Site
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male or female, 18 - 60 years old (inclusive).
- History or presence of fever (≥ 38°C). At least one of the following criteria indicating dengue infection:
- Nausea or vomiting.
- Presence of rash, aches or pains including headache, muscle or joint pain.
- Onset of fever ≤ 48 hours prior to treatment start.
- Positive test on dengue fever.
Exclusion Criteria:
-
Participants with any of abnormalities of clinical laboratory parameters.
-
Usage of any anticoagulant drugs.
-
Current significant medical conditions or illness that the investigator considers should exclude the participants, especially those that require continuation of other medications likely to have an interaction with the study drug.
-
Pregnant or nursing (lactating) women.
-
Clinical signs and symptoms for severe dengue according to Dengue Guideline (WHO 2009) at screening.
-
Participants with any of the following abnormalities of clinical laboratory parameters at screening:
- Hemoglobin <12.0 g/dL in males; <11.0 g/dL in females
- Hematocrit >52 % in males; >46 % in females
- Absolute neutrophil count <1500/μL
- Platelet count <80,000/mm3
- Creatinine >165 μmol/L in males; >130 μmol/L in females
- Serum creatine kinase > 600 U/L
- ALT, AST levels more than 3 X upper limit of normal (ULN)
- Total bilirubin >24 μmol/L
-
Usage of PPIs (proton pump inhibitor) which could affect absorption of EYU688 due to stomach pH value increase up to 48 hours prior to screening.
-
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 4 days after stopping of investigational drug.
-
History or long-QT syndrome, or clinically significant ECG abnormalities, or any of the following ECG abnormalities at screening:
- QTcF > 450 msec (males)
- QTcF > 460 msec (females)
Other protocol-defined inclusion/exclusion criteria may apply.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Comparateur placebo: Placebo
Matching placebo |
Matching placebo administered orally as capsules |
|
Expérimental: EYU688
EYU688 administered by oral route |
EYU688 administered by oral route |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Viremia reduction (viral load reduction (VLR) on log scale) at 48 hours post treatment start
Délai: From predose to 48 hours post treatment start
|
Efficacy assessment of EYU688. It will allow to quantify the viremia reduction at 48 hours post treatment start from baseline. |
From predose to 48 hours post treatment start
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time from fever onset to start of the first 48 hours period during which the oral temperature remained below 37.5℃
Délai: From fever onset to Day 15
|
Efficacy assessment of EYU688. It will allow to assess the time needed between fever onset and defervescence. |
From fever onset to Day 15
|
|
Time from fever onset to the first of two consecutive negative viremia by PCR
Délai: From fever onset to Day 15
|
Efficacy assessment will allow to assess the viremia kinetic from treatment start to Day15 |
From fever onset to Day 15
|
|
Area under the log-transformed viremia curve (AUC) from the first dose to Day 15
Délai: From fever onset to Day 15
|
Efficacy assessment will allow to assess the viremia kinetic from treatment start to Day 15 |
From fever onset to Day 15
|
|
Changes of viral load over time
Délai: From baseline to Day 15
|
Efficacy assessment will allow to assess the viremia kinetic from treatment start to Day15 |
From baseline to Day 15
|
|
Incidence and severity of Adverse Events (AEs)
Délai: From inclusion to Day 15
|
Incidence and severity of AEs by treatment group, including changes in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs. |
From inclusion to Day 15
|
|
Incidence and severity of Serious Adverse Events (SAEs)
Délai: From inclusion to Day 35
|
Incidence and severity of SAEs by treatment group |
From inclusion to Day 35
|
|
Change of white blood cell count over time from baseline
Délai: From baseline to Day 15
|
Assessment of safety and tolerability of EYU688 |
From baseline to Day 15
|
|
Change of platelet count over time
Délai: From baseline to Day 15
|
Assessment of safety and tolerability of EYU688 |
From baseline to Day 15
|
|
Change of hematocrit level and percentage increase from baseline over time
Délai: From baseline to Day 15
|
Assessment of safety and tolerability of EYU688 |
From baseline to Day 15
|
|
Change of AST, ALT levels over time
Délai: From baseline to Day 15
|
Assessment of safety and tolerability of EYU688 |
From baseline to Day 15
|
|
No warning signs by day 7 of fever onset
Délai: From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Diagnosis of severe dengue fever
Délai: From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Diagnosis of dengue hemorrhagic fever (DHF)
Délai: From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Plasma leakage
Délai: From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Requiring fluid infusion
Délai: From inclusion to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From inclusion to Day 15
|
|
Time from fever onset to clinical recovery
Délai: From fever onset to Day 15
|
Assessment of the dengue fever clinical evolution under EYU688 |
From fever onset to Day 15
|
|
PK parameter (Cmax)
Délai: From Day 1 to Day 6
|
Pharmacokinetic assessment of EYU688 in dengue fever patients |
From Day 1 to Day 6
|
|
PK parameter (Tmax)
Délai: From Day 1 to Day 6
|
Pharmacokinetic assessment of EYU688 in dengue fever patients |
From Day 1 to Day 6
|
|
PK parameter (partial AUCs)
Délai: From Day 1 to Day 6
|
Pharmacokinetic assessment of EYU688 in dengue fever patients |
From Day 1 to Day 6
|
|
PK concentrations following multiple doses
Délai: From Day 1 to Day 6
|
Pharmacokinetic assessment of EYU688 in dengue fever patients |
From Day 1 to Day 6
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- CEYU688A12201
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .